

Judith D Goldberg Scd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8980429/publications.pdf>

Version: 2024-02-01

61
papers

1,790
citations

394421

19
h-index

276875

41
g-index

72
all docs

72
docs citations

72
times ranked

3056
citing authors

#	ARTICLE	IF	CITATIONS
1	Focal Irradiation and Systemic TGF β Blockade in Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2493-2504.	7.0	201
2	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 1408-1416.	1.2	175
3	Phase I-II Trial of Prone Accelerated Intensity Modulated Radiation Therapy to the Breast to Optimally Spare Normal Tissue. <i>Journal of Clinical Oncology</i> , 2007, 25, 2236-2242.	1.6	154
4	Prone vs Supine Positioning for Breast Cancer Radiotherapy. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 861.	7.4	138
5	MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. <i>Blood</i> , 2014, 124, 1183-1191.	1.4	135
6	Prospective Assessment of Optimal Individual Position (Prone Versus Supine) for Breast Radiotherapy: Volumetric and Dosimetric Correlations in 100 Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 902-909.	0.8	120
7	Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. <i>Neurology</i> , 2019, 93, e1452-e1462.	1.1	104
8	Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. <i>Blood</i> , 2015, 126, 972-982.	1.4	58
9	Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms. <i>Blood Advances</i> , 2018, 2, 3572-3580.	5.2	51
10	Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy. <i>Clinical Breast Cancer</i> , 2016, 16, 113-122.e1.	2.4	49
11	A randomized phase 3 trial of interferon- γ vs hydroxyurea in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2022, 139, 2931-2941.	1.4	45
12	Prone Breast Intensity Modulated Radiation Therapy: 5-Year Results. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 899-906.	0.8	41
13	Prone Hypofractionated Whole-Breast Radiotherapy Without a Boost to the Tumor Bed: Comparable Toxicity of IMRT Versus a 3D Conformal Technique. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e415-e423.	0.8	40
14	A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). <i>Leukemia Research</i> , 2017, 53, 13-19.	0.8	35
15	Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients. , 2019, 7, 177.		32
16	The effects of outcome misclassification and measurement error on the design and analysis of therapeutic equivalence trials. <i>Statistics in Medicine</i> , 2001, 20, 2065-2078.	1.6	29
17	Phase I dose escalation study of lestaurtinib in patients with myelofibrosis. <i>Leukemia and Lymphoma</i> , 2015, 56, 2543-2551.	1.3	29
18	Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 144, 279-284.	1.4	29

#	ARTICLE	IF	CITATIONS
19	Meta-Analysis to Assess the Appropriate Endpoint for Slow Pathway Ablation of Atrioventricular Nodal Reentrant Tachycardia. PACE - Pacing and Clinical Electrophysiology, 2011, 34, 269-277.	1.2	27
20	Cell cycle features of C. elegans germline stem/progenitor cells vary temporally and spatially. Developmental Biology, 2016, 409, 261-271.	2.0	27
21	Inflammatory cytokines and non-small cell lung cancer in a CT-scan screening cohort: Background review of the literature. Cancer Biomarkers, 2016, 16, 219-233.	1.7	22
22	Pharmacodynamics of natalizumab extended interval dosing in MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	22
23	Increased prevalence of polycythemia vera in parents of patients on polycythemia vera study group protocols. American Journal of Hematology, 1984, 16, 367-373.	4.1	19
24	Prospective Randomized Trial of Prone Accelerated Intensity Modulated Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor Bed. International Journal of Radiation Oncology Biology Physics, 2016, 95, 571-578.	0.8	19
25	A Multicenter, Open Label Phase I/II Study of CEP701 (Lestaurtinib) in Adults with Myelofibrosis; a Report On Phase I: A Study of the Myeloproliferative Disorders Research Consortium (MPD-RC).. Blood, 2009, 114, 754-754.	1.4	19
26	A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).. Blood, 2009, 114, 308-308.	1.4	17
27	Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer. Breast Cancer Research and Treatment, 2018, 168, 57-67.	2.5	15
28	Plasma Zonulin Levels in Childhood Nephrotic Syndrome. Frontiers in Pediatrics, 2019, 7, 197.	1.9	12
29	Surveillance Epidemiology and End Results Analysis Demonstrates Improvement in Overall Survival for Cervical Cancer Patients Treated in the Era of Concurrent Chemoradiotherapy. Frontiers in Oncology, 2015, 5, 81.	2.8	11
30	Results of a phase II study of adjuvant concurrent carboplatin and accelerated radiotherapy for triple negative breast cancer. OncoImmunology, 2017, 6, e1274479.	4.6	10
31	Preplanning prediction of the left anterior descending artery maximum dose based on patient, dosimetric, and treatment planning parameters. Advances in Radiation Oncology, 2016, 1, 373-381.	1.2	9
32	Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibitor, Panobinostat (LBH589), in Patients with Myelofibrosis. Blood, 2011, 118, 794-794.	1.4	9
33	Adherence to guidelines at the patient and hospital levels is associated with improved overall survival in patients with gastric cancer. Journal of Surgical Oncology, 2022, 126, 479-489.	1.7	9
34	Clinical Trial Evidence of the Antitumor Activity of Topical Imiquimod for Breast Cancer Skin Metastases. Journal of Clinical Oncology, 2014, 32, 3204-3205.	1.6	8
35	Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis. Lupus Science and Medicine, 2018, 5, e000271.	2.7	8
36	Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's. Contemporary Clinical Trials, 2021, 107, 106488.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Multifocal Invasive Ductal Cancer: Distinguishing Independent Tumor Foci From Multiple Satellites. International Journal of Surgical Pathology, 2017, 25, 298-303.	0.8	6
38	Likelihood ratio and score tests to test the non-inferiority (or equivalence) of the odds ratio in a crossover study with binary outcomes. Statistics in Medicine, 2016, 35, 3471-3481.	1.6	5
39	Quality of Life in Women Undergoing Breast Irradiation in a Randomized, Controlled Clinical Trial Evaluating Different Tumor Bed Boost Fractionations. International Journal of Radiation Oncology Biology Physics, 2016, 95, 579-589.	0.8	5
40	A Prospective Trial to Compare Deep Inspiratory Breath Hold With Prone Breast Irradiation. Practical Radiation Oncology, 2020, 10, 330-338.	2.1	5
41	Value of metalloproteinases in predicting COPD in heavy urban smokers. Respiratory Research, 2020, 21, 228.	3.6	5
42	071â€¦Natalizumab extended interval dosing (EID) is associated with a significant reduction in progressive multifocal leukoencephalopathy (PML) risk compared with standard interval dosing (SID) in the touch [®] prescribing program. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A29.2-A29.	1.9	4
43	ATIM-37. PHASE II, OPEN-LABEL, SINGLE ARM, MULTICENTER STUDY OF AVELUMAB WITH HYPOFRACTIONATED RADIATION (HFRT) FOR ADULT PATIENTS WITH SECONDARILY TRANSFORMED IDH-MUTANT GLIOBLASTOMA (GBM). Neuro-Oncology, 2019, 21, vi9-vi10.	1.2	3
44	Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer.. Journal of Clinical Oncology, 2017, 35, TPS1124-TPS1124.	1.6	3
45	A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology, 2020, 38, 372-372.	1.6	3
46	Comparison of Clinical Measures Among Interstitial Lung Disease (ILD) Patients with Usual Interstitial Pneumonia (UIP) Patterns on High-Resolution Computed Tomography. Lung, 2020, 198, 811-819.	3.3	2
47	Results of Phase II Clinical Trial MPD-RC 101: Allogeneic Hematopoietic Stem Cell Transplantation Conditioned with Fludarabine/Melphalan in Patients with Myelofibrosis. Blood, 2011, 118, 1750-1750.	1.4	2
48	A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.. Journal of Clinical Oncology, 2014, 32, 5564-5564.	1.6	2
49	Correlation of Novel Molecular Markers in Patients with Myeloproliferative Neoplasms.. Blood, 2009, 114, 4968-4968.	1.4	2
50	Elevated Levels of Urinary Biomarkers TIMP-2 and IGFBP-7 Predict Acute Kidney Injury in Neonates after Congenital Heart Surgery. Journal of Pediatric Intensive Care, 2022, 11, 153-158.	0.8	2
51	Examination of speakership gender disparity at an international oncology conference.. Journal of Clinical Oncology, 2022, 40, 11002-11002.	1.6	2
52	Delivery of adjuvant chemotherapy among stage III colon cancer patients at a public versus private hospital in New York City. Cancer Causes and Control, 2018, 29, 253-260.	1.8	1
53	Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and local radiotherapy in the treatment of breast cancer chest wall recurrences or skin metastases.. Journal of Clinical Oncology, 2013, 31, TPS3122-TPS3122.	1.6	1
54	Statistics in Medicine.. Journal of the American Statistical Association, 1977, 72, 923.	3.1	0

#	ARTICLE	IF	CITATIONS
55	Thrombopoietin Receptor (MPL) Genotype Modifies the Myeloproliferative Phenotype in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera.. Blood, 2009, 114, 964-964.	1.4	0
56	Abnormal P-Selectin Localization During Megakaryocyte Development Determines Thrombosis in the Gata1low Model of Myelofibrosis.. Blood, 2009, 114, 1907-1907.	1.4	0
57	Pathologic response rate in HER2-positive locally advanced breast cancers treated with neoadjuvant trastuzumab and concurrent paclitaxel/radiotherapy.. Journal of Clinical Oncology, 2012, 30, e11064-e11064.	1.6	0
58	Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).. Journal of Clinical Oncology, 2013, 31, 11106-11106.	1.6	0
59	Concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer: A feasibility trial.. Journal of Clinical Oncology, 2014, 32, TPS1147-TPS1147.	1.6	0
60	Methylation profiling of locally advanced rectal cancer (LARC): Exploration of potential predictive markers for neoadjuvant chemoradiation (NACR).. Journal of Clinical Oncology, 2016, 34, 614-614.	1.6	0
61	Progression free survival (PFS) in Asian vs non-Asian patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) receiving osimertinib.. Journal of Clinical Oncology, 2020, 38, e21679-e21679.	1.6	0